SCHEMBL4898720

SCHEMBL4898720

COC(=O)c1cccc(-c2cn(C3CC3)c(=O)n2Cc2ccc(CP(=O)(OF)OF)c(Br)c2)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 2/20 0.36
CHRM3 P20309 2/20 0.36
MAPK10 P53779 3/20 0.35
HIF1A Q16665 1/20 0.35
DPP4 P27487 1/20 0.33
RIPK3 Q9Y572 1/20 0.33
CD74 P04233 1/20 0.33
MIF P14174 1/20 0.33
ALDH1A1 P00352 1/20 0.33
PDE4D Q08499 2/20 0.33
MAPT P10636 1/20 0.32
DGAT2 Q96PD7 1/20 0.32
MET P08581 1/20 0.32
AXL P30530 1/20 0.32
MERTK Q12866 1/20 0.32
CNR2 P34972 1/20 0.32
CHRM2 P08172 1/20 0.31
CHRM4 P08173 1/20 0.31
CHRM5 P08912 1/20 0.31
CHRM1 P11229 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4897265 0.91 MAPK10 (0.37) MAPK8MAPK10HIF1AALDH1A1PDE4D
SCHEMBL4899822 0.91 HRH2 (0.33) HIF1A
SCHEMBL4891960 0.84 GCGR (0.34) MAPK10ALDH1A1
SCHEMBL4898717 0.83 PTPN1 (0.40) MAPK8CHRM3DPP4CD74MIF
SCHEMBL4900432 0.82 NR1H4 (0.31) CNR2
SCHEMBL4895554 0.80 MAPK8 (0.43) MAPK8MAPK10HIF1AALDH1A1CNR2
SCHEMBL4894087 0.80 PPARA (0.36)
SCHEMBL4891992 0.79 MAPK10 (0.39) MAPK8MAPK10HIF1AALDH1A1MAPT
SCHEMBL4890554 0.78 MAPK10 (0.38) MAPK8MAPK10HIF1AALDH1A1
SCHEMBL4901331 0.78 MAPK10 (0.42) MAPK8MAPK10HIF1AALDH1A1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases METABASIS THERAPEUTICS, INC. (US) 2008-03-20 US claimed
WO-2006078698-A1 2-IMIDAZOLONE AND 2-IMIDAZOLIDINONE HETEROCYCLIC INHIBITORS OF TYROSINE PHOSPHATASES CENGENT THERAPEUTICS, INC. (US) 2006-07-27 WO claimed
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases METABASIS THERAPEUTICS, INC. (US) 2008-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases PPM1B, PPM1D, PTPRS MAPK8 682/4885CHRM3 4728/4885MAPK10 656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.